14 November 2022 - FDA approval of extended duration of use supports Medicines360's mission to expand women's access.

Medicines360 announced today that the US FDA has approved Medicines360's supplemental mew drug application to extend the duration of use of Liletta (levonorgestrel releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years.